Medtech Archives - Page 34 of 114 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

FDA Accepts Tris Pharma’s NDA for Once-Nightly, Low-Sodium Oxybate for Narcolepsy and Idiopathic Hypersomnia

December 9, 2025

Delphia Therapeutics Adds Cancer Expert Steve Kelsey, M.D., to Board of Directors

December 9, 2025

Vektor Medical receives FDA 510(k) clearance expanding vMap’s non-invasive cardiac mapping capabilities

December 10, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Medtech

Vektor Medical receives FDA 510(k) clearance expanding vMap’s non-invasive cardiac mapping capabilities

Owlet Launches TGA-Approved Dream Sock in Australia and New Zealand, Expanding Global Reach of Pediatric Health Monitoring

Valvosoft, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis, Receives CE Marking

Aptyx Expands With New Precision Extrusion Center of Excellence in Boston Medtech Corridor

Insulet Announces FDA Clearance for Major Omnipod 5 Algorithm Upgrades

Most Read

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

ImmunityBio Wins EMA Recommendation for Conditional Approval of ANKTIVA With BCG for Bladder Cancer

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

FDA Accepts Tris Pharma’s NDA for Once-Nightly, Low-Sodium Oxybate for Narcolepsy and Idiopathic Hypersomnia

Delphia Therapeutics Adds Cancer Expert Steve Kelsey, M.D., to Board of Directors

Vektor Medical receives FDA 510(k) clearance expanding vMap’s non-invasive cardiac mapping capabilities

POPULAR CATEGORY

ABOUT US

FOLLOW US